Prognostic Significance and Diagnostic Value of Overexpressed lncRNA PVT1 in Colorectal Cancer

被引:9
|
作者
Pan, Xuefeng [1 ]
Cheng, Rui [1 ]
Zhu, Xiaoshan [2 ]
Cai, Fengbo [2 ]
Zheng, Guobao [1 ]
Li, Juntang [2 ]
Gao, Chunfang [2 ]
机构
[1] 989 Hosp Peoples Liberat Army, Dept Oncol, Luoyang 471031, Peoples R China
[2] 989 Hosp Peoples Liberat Army, Inst Anal Colorectal Surg, Luoyang 471031, Peoples R China
关键词
lncRNA; lncRNA PVT1; colorectal cancer; expression; prognosis; LONG NONCODING RNA; CELL-GROWTH; EXPRESSION; STATISTICS; AMPLIFICATION; PROGRESSION; BIOMARKER;
D O I
10.7754/Clin.Lab.2019.190412
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: The aim of this study is to investigate the expression of lncRNA PVT1 in CRC tissue compared to adjacent normal tissues, and reveal the association between lncRNA PVT1 expression level and the clinicopathological characteristics of patients with CRC. Methods: We detected the lncRNA PVT1 relative expression of cancerous tissues in 130 patients with CRC by using real-time quantitative polymerase chain reaction. At the same time, we collected the clinicopathological and prognostic information. Results: IncRNA PVT1 was overexpressed in CRC tissues compared to paired-adjacent normal tissues and the high expression rate was 72.31%. High expression of lncRNA PVT1 predicts a later tumor stage (p = 0.001), poorer tissue differentiation (p = 0.019), and higher plasma CEA level (p = 0.043). Additionally, the lncRNA PVT1 expression was closely related to lymph node metastasis (N1/N2 vs. N0) and distant metastasis (M1 vs. M0) in CRC patients (p = 0.002; p = 0.003), but not to tumor T classification (p = 0.314). The result of prognostic analysis indicated that the 1-year and 3-year DFS of the lncRNA PVT1 low and high expression patients were 93.8% and 81.1%, 69.3% and 44.7%, respectively. The median DFS was 44 months in low expression group and 26 months in high expression group, with statistical significance (p = 0.021). COX multivariate analysis showed that TNM staging (III/IV vs. I/II: HR = 6.342, 95% CI: 2.994 - 13.433, p < 0.001) and the lncRNA PVT1 expression (high expression vs. low expression: HR = 3.744, 95% CI: 1.493 - 9.392, p = 0.005) was closely related to DFS in CRC patients. As with tumor TNM staging, lncRNA PVT1 expression was also an independent prognostic predictor of DFS. The proportion of lncRNA PVT1 high expression (fold change >= 1.725) was higher than that of elevated CEA (> 5 ng/mL) in different CRC stages, especially, there was a significant difference in stage I patients (X-2 = 41.717, p < 0.0001). Conclusions: The lncRNA PVT1 was over-expressed in CRC tissues, which indicated a poor prognosis. The lncRNA PVT1 expression is far higher than the plasma CEA level in the early stage patients, which has the potential diagnostic value for early stage CRC.
引用
收藏
页码:2279 / 2288
页数:10
相关论文
共 50 条
  • [41] Chemokine family significance and prognostic value in colorectal cancer
    Ding, Yi
    Chen, Yinnan
    Xie, Siyun
    Qiu, Quanpeng
    Guo, Xiaolong
    Feng, Yun
    Li, Hongxia
    Zhu, Fang
    Liu, Yaping
    FRONTIERS IN IMMUNOLOGY, 2025, 15
  • [42] Knockdown of lncRNA PVT1 inhibits the proliferation and accelerates the apoptosis of colorectal cancer cells via the miR-761/MAPK1 axis
    Liu, Yujing
    Wu, Yongyou
    Zhu, Zhu
    Gong, Jiangbo
    Dou, Wenhuan
    MOLECULAR MEDICINE REPORTS, 2021, 24 (05)
  • [43] PVT1 Signaling Is a Mediator of Cancer Progression
    Derderian, Camille
    Orunmuyi, Akintunde T.
    Olapade-Olaopa, E. Oluwabunmi
    Ogunwobi, Olorunseun O.
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [44] PVT1 exons 4A, 4B, and 9 are overexpressed in aggressive prostate cancer, and PVT1 exon 4B may distinguish between indolent and aggressive prostate cancer
    Orunmuyi, Akintunde T.
    Ilboudo, Adeodat
    Ogun, Olabiyi G.
    Bach, Cuong
    Adebayo, S. A.
    Salako, Ayo A.
    Olapade-Olaopa, E. Oluwabunmi
    Ogunwobi, Olorunseun O.
    CANCER RESEARCH, 2017, 77
  • [45] The Role of lncRNA PVT1 and hsa-miR-30a-3p in the Development of Gastric Cancer
    Chen, Wenliang
    Fan, Daguang
    Guo, Bo
    Liu, Shuang
    Li, Zhuo
    Duan, Junfang
    Fang, Changzhong
    Liu, Yingtao
    Chen, Lin
    ANNALS OF CLINICAL AND LABORATORY SCIENCE, 2022, 52 (02): : 292 - 300
  • [46] LncRNA PVT1 Regulates TRPS1 Expression Breast Cancer by Sponging miR-543
    Wang, Hongtao
    Huang, Yuanli
    Yang, Yuanrong
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 7993 - 8004
  • [47] LncRNA PVT1 regulates VEGFC through inhibiting miR-128 in bladder cancer cells
    Yu, Cui
    Liu Longfei
    Long, Wang
    Feng, Zeng
    Chen, Jinbo
    Chao, Li
    Liu Peihua
    Zu Xiongbing
    Chen Hequn
    JOURNAL OF CELLULAR PHYSIOLOGY, 2019, 234 (02) : 1346 - 1353
  • [48] lncRNA PVT1 silencing inhibits gastric cancer cells' progression via enhancing chemosensitivity to paclitaxel
    Naseri, Bahar
    Farsad-Akhtar, Nader
    Mardi, Amirhossein
    Baghbani, Elham
    Bornedeli, Soghra
    Asadi, Milad
    Shanehbandi, Dariush
    GENE, 2025, 932
  • [49] LncRNA PVT1 aggravates the progression of glioma via downregulating UPF1
    Lv, Z-H
    Wang, Z-Y
    Li, Z-Y
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2019, 23 (20) : 8956 - 8963
  • [50] Value analysis of ITLN1 in the diagnostic and prognostic assessment of colorectal cancer
    Zhang, Yun
    Gao, Tianyuan
    Wu, Min
    Xu, Zhengyuan
    Hu, Huixian
    TRANSLATIONAL CANCER RESEARCH, 2024, 13 (06) : 2877 - 2891